Skip to content
Loading…
Shares of Moderna and Merck soared on Wednesday morning after a study showed that a vaccine they produced had promising results when it comes to fighting skin cancer. A late-stage trial showed that the mRNA vaccine helped reduce the recurrence of melanoma. Sam Fazeli of…
To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.